Auriga Laboratories, Inc. Announces New Alliance With Degussa To Enhance Product Pipeline Targeting Chronic Gastro-Intestinal Diseases; Technology To Leverage Degussa's Novel EUDRACOL(TM) Technology To Improve Drug Dosing, Efficacy And Reduce Side Effects In GI Tract
8/22/2006 10:56:21 AM
NORCROSS, Ga.--(BUSINESS WIRE)--Aug. 22, 2006--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company dedicated to applying advances in drug delivery to improve and extend the value of medicines for improved patient outcomes and the marketer of the Extendryl(R) family of products, announces the execution of a strategic agreement with Degussa to develop a proprietary formulation targeting serious chronic gastrointestinal diseases utilizing Degussa's proprietary EUDRACOL(TM) technology.
comments powered by